Chronic kidney disease and antidiabetic treatment;Insuffisance rénale chronique et médicaments antidiabétiques

Revue Medicale Suisse

Volumn 3, Issue 101, 2007, Pages 598-604

  Berwert, Lorenzo ^a   Teta, Daniel ^a   Zanchi, Anne ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DRUG METABOLITE; ENZYME INHIBITOR; GLIBENCLAMIDE; GLIBORNURIDE; GLICLAZIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; GENERAL PRACTITIONER; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RISK FACTOR;

BIGUANIDES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 33947603196     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Diabetes control and complications trial/epidemiology of diabetes interventions and complications research group. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
2. Prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837.
3. Global guideline for type 2 diabetes. International diabetes federation 2005: www.idf.org
4. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17:365-70.
5. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53:1343-7.
6. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease :The mild and moderate kidney disease study. J Am Soc Nephrol 2005;16:1091-8.
7. Svensson M, Eriksson JW. Insulin resistance in diabetic nephropathy - cause or consequence ? Diabetes Metab Res Rev 2006;22:401-10.
8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
9. Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-82.
10. De Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-7.
11. Rigalleau V, Gin H. Carbohydrate metabolism in uraemia. Curr Opin Clin Nutr Metab Care 2005;8:463-9.
12. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26:73-85.
13. Mark EW, Bijan R. Role of the new oral hypoglycemic drugs in the diabetic patient with ESRD. Semin Dial 1999;12:25.
14. Krepisnky J, et al. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000;35:500-5.
15. Jonsson A, Rydberg T, Sterner G, et al. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998;53:429-35.
16. Holstein A, Plaschke A, Hammer C, et al. Characteristics and time course of severe glimepiride-versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003;59:91-7.
17. Compendium suisse des médicaments, Documed 2006.
18. Balant L, Zahnd G, Gorgia A, et al. Pharmacokinetics of glipizide in man: Influence of renal insufficiency. Diabetologia 1973;9:331-8.
19. Schernthaner G, Grimaldi A, Di Mario U, et al. Guide study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42.
20. Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: An update. Clin Diabetes 2005;23:64.
21. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes. Diabetes Care 2005;28:2948.
22. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-91.
23. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: A randomized, multicenter study. Diabetes Care 2004;27:1265-70.
24. Inoue T, Shibahara N, Miyagawa K, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003;60:90-5.
25. Nagai T, Imamura M, Iizuka K, et al. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 2003;59:191-4.
26. Stades AM, Heikens JT, Holleman F, et al. Metformin - current restrictions should be alleviated. J Intern Med 2004;256:358.
27. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus : Systematic review and meta-analysis. Arch Intern Med 2003;163:2594-602.
28. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8.
29. Holstein A, Nahrwold D, Hinze S, et al. Contraindications to metformin therapy are largely disregarded. Diabet Med 1999;16:692.
30. Yale J-F. Oral antihyperglycemic agents and renal disease: New agents, new concepts. J Am Soc Nephrol 2005;16(Suppl. 1):7-10.
31. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76.
32. Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368-74.
33. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American heart association and American diabetes association. Circulation 2003;108:2941-8.